CagriSema (cagrilintide + semaglutide)
Cagrilintide + Semaglutide · NN9838 combination
Reviewed by the BestHealingPeptides Editorial Team ·
On this page
A Novo Nordisk fixed-dose combination of semaglutide (the licensed GLP-1 receptor agonist) with cagrilintide (a long-acting amylin analogue) — pairing two appetite-suppressing mechanisms in a single weekly subcutaneous injection. Novo Nordisk submitted a New Drug Application to the US FDA on 18 December 2025 for weight management, and the pivotal REDEFINE 1 and 2 trials were published in NEJM in 2025. In REDEFINE 4, an open-label comparison with tirzepatide 15 mg, Novo Nordisk reported that CagriSema did not meet the primary endpoint of non-inferiority. Not approved in the UK, EU or US as of 29 October 2026.
Mechanism of action
CagriSema pairs two mechanistically distinct appetite-suppressing peptides in a single weekly injection: cagrilintide (a long-acting amylin analogue engaging the calcitonin-receptor family and specifically the amylin receptor complex CTR + RAMP) and semaglutide (the licensed GLP-1 receptor agonist). The pharmacological rationale is complementary rather than redundant — amylin and GLP-1 act through distinct receptor systems in overlapping but non-identical central nervous system circuits regulating appetite and satiety.
Cagrilintide's amylin-mimetic mechanism engages hypothalamic and brainstem calcitonin-family receptors, driving satiety through pathways separate from GLP-1R engagement. Native amylin is co-secreted with insulin from pancreatic β-cells; its physiological role in postprandial satiety complements GLP-1's incretin-effect insulin secretion. The rationale for combining pharmacological amylin and GLP-1 receptor engagement is that the pathways are distinct, so each could contribute independently to reduced caloric intake.
Semaglutide's GLP-1R agonism has been discussed extensively elsewhere on this reference: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central appetite reduction through hypothalamic and brainstem GLP-1R populations. In CagriSema, semaglutide provides the incretin arm; cagrilintide provides the amylin-receptor arm.
A Phase II trial in adults with type 2 diabetes (BMI 27 or higher, on metformin with or without an SGLT2 inhibitor; Frías et al., Lancet 2023; 92 participants) compared cagrilintide 2.4 mg + semaglutide 2.4 mg with each component alone over 32 weeks. Mean weight change was −15.6% with CagriSema, −5.1% with semaglutide alone and −8.1% with cagrilintide alone. In the Phase III REDEFINE 1 trial (adults with obesity without diabetes; Garvey et al., NEJM 2025; 3,417 participants), mean weight change at 68 weeks was −20.4% with CagriSema versus −3.0% with placebo.
This reference found no regulatory approval of cagrilintide as a standalone medicine.
In REDEFINE 1 (Garvey et al., NEJM 2025; 3,417 adults without diabetes), CagriSema produced mean weight change of −20.4% versus −3.0% with placebo over 68 weeks. In the open-label REDEFINE 4 head-to-head trial, Novo Nordisk reported that CagriSema (20.2%) did not meet the primary endpoint of non-inferiority to tirzepatide 15 mg (23.6%) by the treatment-regimen estimand. Novo Nordisk submitted CagriSema to the US FDA on 18 December 2025; it is not approved anywhere as of 29 October 2026.
— Notable finding
Research history
CagriSema is a fixed-dose combination of the long-acting amylin analogue cagrilintide 2.4 mg and the GLP-1 receptor agonist semaglutide 2.4 mg, developed by Novo Nordisk. The combination hypothesis — that amylin and GLP-1 agonism would produce additive weight loss through complementary appetite-regulatory mechanisms — was tested in a Phase 1b trial of cagrilintide with semaglutide 2.4 mg (Enebo et al., Lancet 2021) and a Phase II trial in type 2 diabetes (Frías et al., Lancet 2023).
The Phase III REDEFINE programme includes REDEFINE 1 (obesity without diabetes) and REDEFINE 2 (obesity with type 2 diabetes), both published in NEJM in 2025; REDEFINE 3, a cardiovascular outcomes trial that ClinicalTrials.gov lists as active, not recruiting with primary completion in 2027; and REDEFINE 4, a head-to-head trial against tirzepatide 15 mg. On 23 February 2026 Novo Nordisk announced that in REDEFINE 4 (84 weeks, 809 participants, open-label) CagriSema did not meet the primary endpoint of non-inferiority: weight loss was 20.2% with CagriSema versus 23.6% with tirzepatide by the treatment-regimen estimand, and 23.0% versus 25.5% if all participants adhered to treatment (company-reported).
Novo Nordisk announced on 18 December 2025 that it had submitted a New Drug Application to the US FDA for weight management, based on REDEFINE 1 and 2, and on 23 February 2026 said an FDA decision was anticipated by late 2026. As of 29 October 2026 CagriSema does not appear on the FDA's 2026 novel drug approvals list and is not approved in any jurisdiction. This reference found no announced UK or EU submission.
Reported research-model dose ranges
The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.
| Model | Route | Reported range | Note |
|---|---|---|---|
| Phase II type 2 diabetes (Frías 2023) | Subcutaneous injection | Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly | Both components escalated to 2.4 mg in the 32-week trial. |
| Phase III REDEFINE 1, 2 and 4 and the US FDA submission | Subcutaneous injection | Cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly | Dose described in Novo Nordisk's 18 December 2025 announcement of the FDA submission. The titration schedule is not given in the sources used for this reference. |
| Not for research-chemical use | Not applicable | Not applicable | Combination product not appropriate for research-chemical-community assembly. |
Reconstitution & storage
Summarised studies
| Year | Model | Outcome | Citation | Source |
|---|---|---|---|---|
| 2023 | Adults with type 2 diabetes and BMI 27 or higher, Phase II RCT | Weight change −15.6% (CagriSema) versus −5.1% (semaglutide) and −8.1% (cagrilintide) at 32 weeks | Frías JP, Deenadayalan S, Erichsen L, et al. Lancet. 2023;402(10403):720-730 | PMID 37364590 |
| 2021 | Adults with overweight (otherwise healthy), Phase 1b RCT | Half-life 159-195 h (cagrilintide) and 145-165 h (semaglutide); no effect of cagrilintide on semaglutide exposure | Enebo LB, Berthelsen KK, Kankam M, et al. Lancet. 2021;397(10286):1736-1748 | PMID 33894838 |
| 2025 | Adults with overweight or obesity without diabetes, Phase III RCT | −20.4% (CagriSema) versus −3.0% (placebo) mean weight change at 68 weeks | Garvey WT, et al. N Engl J Med. 2025 (REDEFINE 1; NCT05567796) | PMID 40544433 |
| 2025 | Adults with overweight or obesity and type 2 diabetes, Phase III RCT | −13.7% (CagriSema) versus −3.4% (placebo) mean weight change at 68 weeks | Davies MJ, et al. N Engl J Med. 2025 (REDEFINE 2; NCT05394519) | PMID 40544432 |
| 2026 | Adults with obesity, open-label Phase III RCT | Company-reported: non-inferiority to tirzepatide 15 mg not shown (20.2% vs 23.6%) | Novo Nordisk company announcement, 23 February 2026 (NCT06131437); not located in a journal | — |
Cagrilintide-semaglutide 2.4 mg once weekly in adults with type 2 diabetes (Phase 2 trial)
Frías JP, Deenadayalan S, Erichsen L, et al. Lancet. 2023;402(10403):720-730 · 2023 · PMID 37364590
Phase II 32-week trial in 92 adults with type 2 diabetes and BMI 27 or higher on metformin with or without an SGLT2 inhibitor, comparing cagrilintide + semaglutide (CagriSema) with semaglutide alone and cagrilintide alone, all escalated to 2.4 mg. Mean weight change was −15.6% with CagriSema, −5.1% with semaglutide and −8.1% with cagrilintide; HbA1c changed by −2.2, −1.8 and −0.9 percentage points. CagriSema was superior to cagrilintide for HbA1c but not significantly different from semaglutide.
PubMedCagrilintide alone and in combination with semaglutide in overweight adults (Phase 1b trial)
Enebo LB, Berthelsen KK, Kankam M, et al. Lancet. 2021;397(10286):1736-1748 · 2021 · PMID 33894838
Randomised, placebo-controlled, multiple-ascending-dose Phase 1b trial in otherwise healthy adults aged 18-55 with BMI 27.0-39.9 (96 randomised, 95 exposed) of cagrilintide 0.16-4.5 mg added to semaglutide 2.4 mg. Most adverse events were mild to moderate. Half-life was 159-195 hours for cagrilintide and 145-165 hours for semaglutide 2.4 mg, and cagrilintide did not affect semaglutide exposure or elimination.
PubMedCoadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1)
Garvey WT, et al. N Engl J Med. 2025 (REDEFINE 1; NCT05567796) · 2025 · PMID 40544433
Phase 3a, 68-week, double-blind trial in 3,417 adults without diabetes randomised to cagrilintide 2.4 mg + semaglutide 2.4 mg, semaglutide alone, cagrilintide alone or placebo. By the treatment-policy estimand, mean weight change was −20.4% with CagriSema versus −3.0% with placebo (estimated difference −17.3 percentage points). Gastrointestinal adverse events affected 79.6% of the CagriSema group and 39.9% of the placebo group.
PubMedCagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2)
Davies MJ, et al. N Engl J Med. 2025 (REDEFINE 2; NCT05394519) · 2025 · PMID 40544432
Phase 3a, 68-week, double-blind trial in 1,206 adults with type 2 diabetes and BMI 27 or higher randomised 3:1 to CagriSema 2.4 mg/2.4 mg or placebo. By the treatment-policy estimand, mean weight change was −13.7% versus −3.4%; 73.5% of the CagriSema group reached HbA1c of 6.5% or less versus 15.9% with placebo.
PubMedCagriSema versus tirzepatide 15 mg in adults with obesity (REDEFINE 4)
Novo Nordisk company announcement, 23 February 2026 (NCT06131437); not located in a journal · 2026
Open-label 84-week trial in 809 randomised adults with obesity and one or more comorbidities comparing CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg. Novo Nordisk reported weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide by the treatment-regimen estimand (23.0% versus 25.5% if all adhered to treatment) and that the trial did not meet its primary endpoint of non-inferiority. These are company-reported figures.
Safety profile
CagriSema is not approved, so there is no UK Summary of Product Characteristics; the figures below come from published trials and company announcements. In REDEFINE 1 (Garvey et al., NEJM 2025), gastrointestinal adverse events affected 79.6% of participants on CagriSema and 39.9% on placebo, mainly transient and mild to moderate. Novo Nordisk reported that these included nausea (55% vs 12.6%), constipation (30.7% vs 11.6%) and vomiting (26.1% vs 4.1%), and that discontinuations due to adverse events were 5.9% with CagriSema versus 3.5% with placebo in REDEFINE 1, and 8.4% versus 3% in REDEFINE 2 (Novo Nordisk, 18 December 2025).
In REDEFINE 2 (adults with type 2 diabetes; Davies et al., NEJM 2025), gastrointestinal adverse events were reported by 72.5% on CagriSema and 34.4% on placebo. In the Phase II trial in type 2 diabetes (Frías et al., Lancet 2023), adverse events were reported by 68% of the CagriSema group, 71% of the semaglutide group and 80% of the cagrilintide group; no level 2 or 3 hypoglycaemia and no fatal adverse events were reported.
The cardiovascular outcomes trial REDEFINE 3 (NCT05669755) is listed on ClinicalTrials.gov as active, not recruiting, with primary completion in 2027. This reference does not state a class warning for CagriSema because none has been issued in an approved label.
Reported contraindications & cautions
- Not a licensed medicine — there is no UK Summary of Product Characteristics and no formal contraindication list
- Semaglutide, one component, is licensed separately and has its own UK product information; see the semaglutide entry
Known formulation interactions
- No approved product information exists for the combination, so no interaction list can be cited. See the semaglutide entry for the licensed component.
UK regulatory status
CagriSema is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction as of 29 October 2026. Novo Nordisk submitted a New Drug Application to the US FDA on 18 December 2025 and said an FDA decision was anticipated by late 2026; the FDA's 2026 novel drug approvals list (current to 20 October 2026) does not include it. This reference found no announced MHRA or EMA submission and makes no prediction about UK availability.
Without a marketing authorisation, CagriSema is not available as a medicine through MHRA-regulated UK channels. Semaglutide is licensed on its own, but the combination with cagrilintide is not. Supply for human use outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012.
CagriSema and its components are not named on the WADA Prohibited List; WADA's S0 category covers pharmacological substances not addressed elsewhere on the List that have no current government approval for human therapeutic use, so athletes should check its status with their anti-doping organisation. Not a controlled drug under the Misuse of Drugs Act 1971. For animal research under ASPA, both component peptides require standard project and personal licences.
Frequently asked questions
What is CagriSema?
How does the combination produce additive weight loss?
How does CagriSema compare with tirzepatide?
Is CagriSema available in the UK?
What is cagrilintide?
What do the published REDEFINE 1 and 2 trials of CagriSema show?
Is CagriSema prohibited in sport?
References
- Cagrilintide-semaglutide 2.4 mg once weekly in adults with type 2 diabetes (Phase 2 trial). Frías JP, Deenadayalan S, Erichsen L, et al. Lancet. 2023;402(10403):720-730 (2023). PMID 37364590
- Cagrilintide alone and in combination with semaglutide in overweight adults (Phase 1b trial). Enebo LB, Berthelsen KK, Kankam M, et al. Lancet. 2021;397(10286):1736-1748 (2021). PMID 33894838
- Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). Garvey WT, et al. N Engl J Med. 2025 (REDEFINE 1; NCT05567796) (2025). PMID 40544433
- Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). Davies MJ, et al. N Engl J Med. 2025 (REDEFINE 2; NCT05394519) (2025). PMID 40544432
- CagriSema versus tirzepatide 15 mg in adults with obesity (REDEFINE 4). Novo Nordisk company announcement, 23 February 2026 (NCT06131437); not located in a journal (2026).
- Frías et al. 2023 — Phase II CagriSema in type 2 diabetes (PMID 37364590)
- Enebo et al. 2021 — Phase Ib foundational (PMID 33894838)
- Garvey et al. 2025 — REDEFINE 1, NEJM (PMID 40544433)
- Davies et al. 2025 — REDEFINE 2, NEJM (PMID 40544432)
- Novo Nordisk — FDA submission of CagriSema, 18 December 2025
- Novo Nordisk — REDEFINE 4 headline results, 23 February 2026
- Novo Nordisk — REIMAGINE 5 headline results, 21 September 2026
- PubChem — cagrilintide (CID 171397054)
- ClinicalTrials.gov — REDEFINE programme
- MHRA — UK medicines regulator
Where to source CagriSema (cagrilintide + semaglutide) for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.
Related peptides
Semaglutide
A long-acting GLP-1 receptor agonist developed by Novo Nordisk, modified from native GLP-1 with aminoisobutyric acid (Aib) at position 8 (DPP-4 resistance) and a C18 fatty diacid moiety on lysine 26 (albumin binding for ~1-week half-life). Licensed in the UK by the MHRA for type-2 diabetes (Ozempic, subcutaneous; Rybelsus, oral) and chronic weight management (Wegovy, subcutaneous injection and oral tablets). The most clinically significant GLP-1 receptor agonist of the late 2020s.
Tirzepatide
A dual GIP and GLP-1 receptor agonist: an amino acid sequence with a C20 fatty diacid moiety that enables albumin binding, giving an elimination half-life of approximately 5 days and once-weekly subcutaneous dosing. Licensed in the UK as Mounjaro (KwikPen), a prescription only medicine for type 2 diabetes in adults, adolescents and children aged 10 years and above and for weight management in adults (Zepbound is the US brand only). In the head-to-head SURPASS-2 and SURMOUNT-5 trials tirzepatide produced greater HbA1c reduction and weight loss than semaglutide.
Retatrutide
An Eli Lilly triple agonist of the GLP-1, GIP, and glucagon receptors — an extension of tirzepatide's dual-agonist mechanism with added glucagon-receptor activation. Phase II results (Jastreboff et al., NEJM 2023) showed 24.2% mean body weight loss over 48 weeks at the 12 mg dose, and the Phase III TRIUMPH-1 trial (Jastreboff et al., NEJM 2026) reported 25.0% at 12 mg over 80 weeks versus 3.9% with placebo. Not approved in any jurisdiction as of 29 October 2026; Eli Lilly has said it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027.
Orforglipron
An oral, non-peptide GLP-1 receptor agonist taken as a once-daily tablet. Orforglipron (Foundayo, Eli Lilly) was approved by the US FDA on 1 April 2026 for adults with obesity or overweight, and was authorised by the MHRA in the UK on 10 August 2026 for weight management and for insufficiently controlled type 2 diabetes in adults. In the UK it is a prescription only medicine supplied as film-coated tablets in six strengths from 0.8 mg to 17.2 mg, taken at any time of day without food or water restriction (UK SmPC section 4.2). The CHMP adopted a positive opinion for the EU on 15 October 2026; a European Commission decision had not been confirmed when this page was last updated. The gov.uk announcement states that it is not currently available via the NHS.
Survodutide
A Boehringer Ingelheim dual GLP-1/glucagon receptor agonist, licensed from Zealand Pharma — a two-receptor mechanism intermediate between semaglutide's single GLP-1R agonism and retatrutide's triple GLP-1R/GIPR/glucagon-R agonism. The GLP-1 + glucagon combination pairs appetite suppression (GLP-1R) with proposed energy-expenditure enhancement (glucagon-R) without the additional GIPR dimension of retatrutide. The Phase III SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD trials were published in 2026; survodutide remains investigational and is not approved in any jurisdiction (Zealand Pharma company announcement, 1 October 2026).